VRVeena K. Ranganath

Veena K. Ranganath

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Veena K. Ranganath has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    TIDAL: A Temporal Causal Diffusion Framework for Visualizing Knee Osteoarthritis Treatment Outcomes

    by Anthony Cuturrufo, Fred Xu, Arvind M. Vepa, David Bakal, Veena K. Ranganath, Yizhou Sun, Wei Wang


  • Open Access

    Relative muscle mass is preserved during weight loss in rheumatoid arthritis: a post-hoc RCT analysis

    by David A Kellner, Joshua F Baker, Sitaram Vangala, David A Elashoff, Jin Long, Veena K Ranganath

    Objectives: Obesity and sarcopenia commonly coexist in RA, compounding metabolic risk and disability. Intentional weight loss may improve outcomes but raises concern for accelerated muscle loss. We conducted a post-hoc analysis of a randomized controlled trial (RCT) of a hypocaloric, high-protein diet in adults with RA and obesity to determine whether diet-induced weight loss was associated with disproportionate reductions in muscle mass. Methods: Adults with RA and obesity were randomized to a 12-week hypocaloric, high-protein diet or to control dietary advice (NCT02881307). DXA was performed at baseline and 12 weeks. Fat mass index (FMI), appendicular lean mass index (ALMI) and adiposity-adjusted ALMI (ALMIFMI) were derived and standardized to Z-scores using national reference data. Between-group differences in change were compared using t-tests, with FDR-adjusted P values reported for all analyses. Results: Participants in the dietary intervention achieved significant reductions in total fat mass (mean change in FMI Z-score −0.35 vs 0.04; P = 0.003). Changes in ALMI Z-score (−0.37 vs −0.43; P = 0.92) and ALMIFMI Z-score (−0.15 vs −0.55; P = 0.92) did not differ significantly between groups. In the intervention group there was minimal decline in ALMFMI, suggesting parallel reductions in lean and fat tissue. Conclusion: In adults with RA and obesity, diet-induced weight loss reduced adiposity without evidence of disproportionate muscle loss. These findings support the safety of structured, protein-adequate weight-loss interventions in this population.

  • The promise of imaging in psoriatic arthritis

    by David A. Kellner, Illiasul K. Ibad, Janeth Yinh, Catherine Bakewell, Erin Chew, Philip Chu, Ann Cameron Barr, Howard H. Yang, Madhavi Kandagaddala, Ashish J. Mathew, et al.

  • Open Access

    Rheumatoid arthritis in crisis: investigating the impact of stress on RA flares during the COVID-19 pandemic

    by Nicolette T. Morris, Thasia Woodworth, Angela Pham, David A. Elashoff, Jenny Brook, Daniel E. Furst, Veena K. Ranganath

    Introduction/objectives: Psychological stress impacts rheumatoid arthritis (RA) disease activity, and California’s response to the COVID-19 pandemic created historically significant stressors for patients. This study examined factors associated with changes in RA flares during the pandemic. Methods: In this cross-sectional COVID-19 RA study, patients with RA ICD-9/10 codes were emailed a questionnaire in July/November of 2020 containing questions on RA disease activity, Routine Assessment of Patient Index Data 3 (RAPID3), flare number and frequency, RA Flare Questionnaire (RA-FQ), Perceived Stress Scale 4 (PSS-4), stressors, and demographics. Age, anti-cyclic citrullinated antibody, and rheumatoid factor were extracted from medical records. Analyses examined associations between current flare status, number of flares, and changes in flare frequency with PSS-4 and stressors. Results: Of 1138 respondents (22.6% response rate), 69.3% reported at least one RA flare, 43% multiple flares, and 36.3% currently experiencing a flare. Compared to pre-pandemic levels, 36.3% noted more frequent flares, while 9.2% reported fewer. Increased stress was noted across all flare groups. Regression analyses revealed significant associations between current flare and PSS-4 scores, financial stress, and sleep quality (all p < 0.03). A higher number of flares were significantly associated with PSS-4, financial stress, and home stress ( p < 0.03). Increased flare frequency was associated with PSS-4, apprehension, panic, financial stress, and sleep quality (all p < 0.05). Asian race was negatively associated with the number of flares and flare frequency (both p < 0.05). Conclusions: This study reports a link between stress and RA flares during the pandemic, underscoring the need for targeted strategies to manage RA patients at risk of flare during heightened stress. Key Points • During the COVID-19 pandemic, patient-reported RA flares increased significantly compared to pre-pandemic levels, signifying there may be value in reevaluating RA management strategies during periods of heightened stress. • Financial stress, home stress, and poor sleep were major pandemic stressors linked to current and increased frequency of RA flares. • RA patients not in remission may be more susceptible to disease exacerbations while under stress, as those experiencing flares during the pandemic were less likely to have been in remission beforehand. • Asian race was associated with fewer RA flares and reduced flare frequency, suggesting racial and ethnic differences may influence flare patterns.


  • Open Access

    Use of Rituximab to Attempt Recapture of Immune Tolerance to Pegloticase

    by John D. FitzGerald, Rita Kachru, Chen Xie, Veena K. Ranganath

    Patients suffering from erosive tophaceous gout who have failed oral urate-lowering therapies and pegloticase have few therapeutic options. Pegloticase failure (infusion reaction or lack of urate lowering) is primarily due to the development of anti-drug antibodies, and once present, retreating with pegloticase is mostly unsuccessful. We postulated that rituximab pre-treatment might permit recapture of pegloticase immune tolerance. We conducted an open label, safety and feasibility study to test this hypothesis. Patients with tophaceous gout and prior pegloticase failure were recruited to receive rituximab 1000 mg (twice), methotrexate 15 mg by mouth for at least 6 weeks, and then pegloticase per standard protocol. Patients were observed for infusion reaction and serum urate lowering in response to pegloticase infusions. Two patients completed induction and received at least 1 dose of pegloticase. Patient 1 had a moderate infusion reaction, requiring treatment with oral prednisone. Patient 2 had failure to lower urate treatment after 2 infusions. Based on these 2 outcomes, the trial was stopped. With either 6- or 12-week pre-pegloticase conditioning with rituximab, we were unable to recapture immune tolerance. Future trials considering use of rituximab might consider measuring anti-uricase antibodies in real time to guide the reintroduction of pegloticase.

  • Open Access

    Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis

    by David A. Kellner, Elizabeth Dente, Vincent Tran, Travis Welsh, Victor Tran, Angshuman Saha, Joshua F. Baker, David A. Elashoff, Veena K. Ranganath

    Objective: Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) are approved for weight loss, diabetes, and cardiovascular risk reduction. Despite widespread use, GLP‐1RAs have not been well studied in patients with rheumatoid arthritis (RA). We examined the effects of GLP‐1RAs on RA disease activity and cardiovascular risk profile in patients with RA and overweight or obesity.Methods: We conducted a retrospective chart review study of patients with RA with a body mass index of ≥27 who were prescribed a GLP‐1RA (semaglutide or tirzepatide). Between 2018 and 2024, 173 patients with RA were identified in the treatment group (prescribed and took a GLP‐1RA), and 42 patients with RA were identified in the control group (prescribed but did not take GLP‐1RA). Patients were assessed at three‐month intervals for up to one year after prescription. Outcome measures included RA disease activity, cardiovascular risk markers, and patient‐reported outcomes. Changes in outcome measures within and between groups were assessed with linear mixed effect models, with adjustments for baseline characteristics that differed significantly between groups.Results: GLP‐1RA–treated patients experienced significantly greater reductions in RA disease activity, pain, body weight, total cholesterol, and glycosylated hemoglobin than controls (P < 0.05). Within the treatment group, there were also significant reductions in erythrocyte sedimentation rate, C‐reactive protein values, low‐density lipoprotein cholesterol values, and triglyceride values (P < 0.05). Nearly one‐third of the treatment group discontinued the GLP‐1RA during the study period, with the most common adverse effect being gastrointestinal issues.Conclusion: This study suggests that the use of GLP‐1RAs can improve RA disease activity and cardiovascular risk profile. Although further research is needed, this novel finding has significant clinical implications because it suggests that anti‐obesity medications may improve both cardiovascular and RA outcomes.


  • Clinical utility of ultrasound and MRI in rheumatoid arthritis: An expert review

    by David A. Kellner, Nicolette T. Morris, Stephanie M. Lee, Joshua F. Baker, Philip Chu, Veena K. Ranganath, Gurjit S. Kaeley, Howard H. Yang


  • Open Access

    Ultrasound Findings of Monosodium Urate Aggregates in Patients with Gout

    by Eric Liu, Nicola Dalbeth, Bregina Pool, Andrea Ramirez Cazares, Veena K. Ranganath, John D. FitzGerald

    Aggregates are one of the elementary lesions seen on musculoskeletal ultrasound (US) in gout patients as defined by Outcome Measures in Rheumatology (OMERACT). The aim of this study was to evaluate the threshold of detection of aggregate findings on ultrasound and to analyze these findings with corresponding compensated light microscope (CPLM) images in vitro. Patient derived monosodium urate (MSU) crystals were obtained from two separate patients with gout during routine clinical care. In addition, fabricated in-house synthetic MSU crystals were used for comparison. Each sample was scanned using a GE Logic ultrasound machine and corresponding CPLM images obtained. As the aggregates became imperceptible by ultrasound, MSU clumping by CPLM examination was no longer detectable and crystal density per high power field fell markedly. Aggregates on US images are present only from patient-derived samples likely representing MSU crystal clustering or packing. Thus, when synovial aspiration is considered, a joint with aggregates on US would be a more suitable target with a higher likelihood of noting MSU crystals.


  • Open Access

    Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis

    by Christina Charles-Schoeman, Jennifer Wang, Ani Shahbazian, Holly Wilhalme, Jenny Brook, Gurjit S. Kaeley, Buzand Oganesian, Ami Ben-Artzi, David A. Elashoff, Veena K. Ranganath

    Active rheumatoid arthritis (RA) is associated with increased cardiovascular risk and impaired function of high-density lipoprotein (HDL). Previous work suggests that HDL may become dysfunctional through oxidative modifications within the RA joint. The current work evaluates an association of synovial power doppler ultrasound signal (PDUS) with HDL function and structure. Two open-label clinical therapeutic studies using PDUS as a disease outcome measure were included in this analysis, including a 12-month trial of subcutaneous abatacept in 24 RA patients and a 6-month trial of IV tocilizumab in 46 RA patients. Laboratory assays included assessments of HDL function and structure, HDL and total cholesterol levels, and a cytokine/chemokine panel. Patients with the highest baseline PDUS scores in both clinical studies, had worse HDL function, including suppression of paraoxonase 1 (PON1) activity as well as lower HDL-C levels. Associations between other disease assessments (DAS28 and CDAI) and HDL function/structure were noted but were generally of lesser magnitude and consistency than PDUS across the HDL profile. Treatment with tocilizumab for 6 months was associated with increases in cholesterol levels and improvements in the HDL function profile, which correlated with greater decreases in PDUS scores. Similar trends were noted following treatment with abatacept for 3 months. Higher baseline PDUS scores identified patients with worse HDL function. This data supports previous work suggesting a direct association of joint inflammation with abnormal HDL function.


  • Open Access

    Optimizing Reliability of Real-Time Sonographic Examination and Scoring of Joint Synovitis in Rheumatoid Arthritis

    by Veena K. Ranganath, Ami Ben-Artzi, Jenny Brook, Yosra Suliman, Astrid Floegel-Shetty, Thasia Woodworth, Mihaela Taylor, Laurie A Ramrattan, David Elashoff, Gurjit S. Kaeley

    Objective: Musculoskeletal ultrasound real-time image acquisition and scoring are complex, and many factors affect reliability. Static image reliability does not guarantee real-time scoring. This study aimed to identify factors and solutions to improve real-time scoring reliability for the grey scale and power Doppler evaluation of synovitis. We also report on using a novel musculoskeletal ultrasound synovitis rule-based scoring atlas. Methods: In four stages, we evaluated inter- and intra-reader reliability among three ultrasonographers (US1-3). Intra- and inter-reader reliability was calculated using weighted-kappa, intraclass correlation coefficient, and Spearman correlation. Reliability statistics were compared between stages using permutation tests to compute empirical distributions for differences in those statistics. At each stage, factors that diminished reliability were identified and addressed. After intensive reliability exercises, a RA MSUS atlas with in-depth scoring rules was generated to improve interpretive reliability. Results: The three ultrasonographers had good to excellent intra-reader reliability for real-time acquisition scoring over 2432 views (weighted kappa 0.52-0.80, intraclass correlation coefficient 0.59-0.86, and Spearman correlation 0.64-0.86). Inter-reader reliability was good to excellent between US1/US2 and US1/US3 (weighted kappa 0.51-0.66, intraclass correlation coefficient 0.66-0.75, Spearman correlation 0.59-0.73). US1 achieved significant improvement in intra-reader reliability from stage 1 to stage 2 (p<0.05, weighted-kappa 0.63 to 0.80, intraclass correlation coefficient 0.71 to 0.86, Spearman 0.67 to 0.86) with use of the atlas. Conclusion: This rheumatoid arthritis musculoskeletal ultrasound study addressed complex factors affecting musculoskeletal ultrasound acquisition-scoring reliability. Systematic identification and amelioration of many factors and using a novel rule-based scoring atlas significantly improved intra-reader reliability.